Barclays Lowers Kenvue (NYSE:KVUE) Price Target to $22.00

Kenvue (NYSE:KVUE - Free Report) had its price objective cut by Barclays from $23.00 to $22.00 in a report released on Monday morning,Benzinga reports. They currently have an equal weight rating on the stock.

Several other analysts have also commented on the stock. Piper Sandler increased their target price on shares of Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. Citigroup cut their price objective on Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a report on Wednesday, January 15th. Redburn Atlantic initiated coverage on shares of Kenvue in a research report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 target price on the stock. UBS Group decreased their price objective on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research note on Friday, February 7th. Finally, Royal Bank of Canada reissued a "sector perform" rating and set a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Eight analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, Kenvue currently has a consensus rating of "Hold" and an average target price of $24.42.

Kenvue Stock Performance

Shares of KVUE traded up $0.69 during trading hours on Monday, reaching $23.42. 22,595,142 shares of the company's stock traded hands, compared to its average volume of 17,057,845. The firm has a market capitalization of $44.93 billion, a price-to-earnings ratio of 44.19, a P/E/G ratio of 2.62 and a beta of 1.02. The business's fifty day simple moving average is $22.91 and its two-hundred day simple moving average is $22.41. Kenvue has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Analysts predict that Kenvue will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th will be given a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a yield of 3.50%. Kenvue's payout ratio is currently 154.72%.

Institutional Trading of Kenvue

Institutional investors and hedge funds have recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its holdings in Kenvue by 3.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock worth $5,249,665,000 after acquiring an additional 8,211,748 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Kenvue by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company's stock worth $4,665,908,000 after buying an additional 1,636,741 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in Kenvue by 12.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock valued at $2,085,070,000 after purchasing an additional 10,682,003 shares during the last quarter. Geode Capital Management LLC grew its position in Kenvue by 3.1% during the fourth quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company's stock worth $980,989,000 after buying an additional 1,391,854 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in shares of Kenvue by 61.5% in the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock worth $912,059,000 after acquiring an additional 16,269,721 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.